Results 1 to 10 of about 9,052 (66)

Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial. [PDF]

Trials, 2022
Rojo P, Moraleda C, Tagarro A, Domínguez-Rodríguez S, Castillo LM, Tato LMP, López AS, Manukyan L, Marcy O, Leroy V, Nardone A, Burger D, Bassat Q, Bates M, Moh R, Iroh Tam PY, Mvalo T, Magallhaes J, Buck WC, Sacarlal J, Musiime V, Chabala C, Mujuru HA.   +22 more
europepmc   +1 more source

Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. [PDF]

PLoS One, 2011
Levit A, Yarnitzky T, Wiener A, Meidan R, Niv MY.   +4 more
europepmc   +1 more source

Impaired endocytosis in proximal tubule from subchronic exposure to cadmium involves angiotensin II type 1 and cubilin receptors. [PDF]

BMC Nephrol, 2013
Santoyo-Sánchez MP, Pedraza-Chaverri J, Molina-Jijón E, Arreola-Mendoza L, Rodríguez-Muñoz R, Barbier OC.   +5 more
europepmc   +1 more source

Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. [PDF]

PLoS Biol, 2012
Shulha HP, Crisci JL, Reshetov D, Tushir JS, Cheung I, Bharadwaj R, Chou HJ, Houston IB, Peter CJ, Mitchell AC, Yao WD, Myers RH, Chen JF, Preuss TM, Rogaev EI, Jensen JD, Weng Z, Akbarian S.   +17 more
europepmc   +1 more source

First isolation of viable Toxoplasma gondii from a black mangabey (Lophocebus aterrimus) reveals the emergence of the Africa 1 lineage in East Asia. [PDF]

PLoS Negl Trop Dis
Ma Y, Yang L, Yang Y.
europepmc   +1 more source

Disordered clock protein interactions and charge blocks turn an hourglass into a persistent circadian oscillator. [PDF]

Nat Commun
Jankowski MS, Griffith D, Shastry DG, Pelham JF, Ginell GM, Thomas J, Karande P, Holehouse AS, Hurley JM.   +8 more
europepmc   +1 more source

Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines

European Journal of Pharmaceutical Sciences, 2000
Douwe Breimer, Albertus G de Boer, A G de Boer   +2 more
exaly  

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007

Cancer Letters, 2018
Naoise Synnott, Stephen F Madden, John Crown   +2 more
exaly